49 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
13 May 24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:15am
the initiation of our Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease (CKD). We
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression. Beyond the organ transplant setting, our Facilitated
8-K
EX-99.1
0roeh3phkv1z
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
mt9ycqo
8 Jan 24
Regulation FD Disclosure
9:19am
425
udjkno8uefvt1
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
bh8svos
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
tmgoyq jl9o
15 Sep 23
Prospectus supplement
6:31am
425
jsr34m53
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
wrv6rrewbimbwi3
13 Sep 23
Regulation FD Disclosure
9:13am
S-4/A
vdvcg5
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
CORRESP
4jy40am uuz68
25 Aug 23
Correspondence with SEC
12:00am
UPLOAD
cuhyoi11g9vbogqag
16 Aug 23
Letter from SEC
12:00am
S-4
94qaay 74ayc4
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
8-K
EX-99.2
a5fhy grjcl5gx
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am